Biomarin Pharmaceutical Inc
NASDAQ:BMRN

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Watchlist
Price: 56.3 USD -1.21% Market Closed
Market Cap: $10.8B

Net Margin

16.8%
Current
Improving
by 6.1%
vs 3-y average of 10.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16.8%
=
Net Income
$520.4m
/
Revenue
$3.1B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16.8%
=
Net Income
$520.4m
/
Revenue
$3.1B

Peer Comparison

Country Company Market Cap Net
Margin
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
10.8B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.8B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.3B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Higher than 79% of companies in the United States of America
Percentile
79th
Based on 15 072 companies
79th percentile
16.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Biomarin Pharmaceutical Inc
Glance View

In the bustling hub of biotechnology innovation, BioMarin Pharmaceutical Inc. stands as a notable entity, driven by its mission to transform medical research into meaningful treatments for patients worldwide. Founded in 1997 and headquartered in San Rafael, California, BioMarin has carved a niche in the competitive landscape by specializing in therapies for rare genetic diseases. The company navigates the arduous and often uncertain path of drug development by targeting serious, and typically overlooked, medical conditions. BioMarin's expertise lies in leveraging cutting-edge genetic knowledge and technological advances to develop biopharmaceuticals that address unmet medical needs. This focus not only guides its scientific explorations but also informs its business strategy, where the development of drugs like Vimizim and Palynziq for conditions such as Morquio A syndrome and phenylketonuria, respectively, have made substantial impacts. BioMarin's revenue stream is predominantly fueled by these specialized therapies that cater to niche markets, with patients who often have limited treatment alternatives. Unlike traditional pharmaceuticals, BioMarin's portfolio is characterized by its strategic focus on orphan diseases, allowing it to capitalize on regulatory incentives designed to encourage the development of treatments for rare disorders. This approach provides market exclusivity and premium pricing potential, contributing to its financial robustness. Additionally, BioMarin's continuous investment in research and development ensures a dynamic pipeline aiming to introduce new innovations. This cycle of discovery and commercialization effectively sustains its growth trajectory, allowing BioMarin to not only thrive financially but also deliver on its commitment to improve patient lives with ultra-rare conditions.

BMRN Intrinsic Value
88.53 USD
Undervaluation 36%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
16.8%
=
Net Income
$520.4m
/
Revenue
$3.1B
What is Biomarin Pharmaceutical Inc's current Net Margin?

The current Net Margin for Biomarin Pharmaceutical Inc is 16.8%, which is above its 3-year median of 10.7%.

How has Net Margin changed over time?

Over the last 3 years, Biomarin Pharmaceutical Inc’s Net Margin has increased from 4.2% to 16.8%. During this period, it reached a low of 3.3% on Mar 31, 2023 and a high of 21.5% on Jun 30, 2025.

Back to Top